在局部晚期宫颈癌和阴道癌的顺铂放化疗中加入曲阿平(T):NRG-GY006 Ⅲ期随机试验结果
NRG-GY006 是一项开放标签随机Ⅲ期试验,纳入 450 例局部晚期宫颈癌或阴道癌患者,随机接受顺铂放化疗(CRT)或 CRT 联合曲阿平(CRT+T)。中位随访 28 个月,死亡 HR 为 1.018(95%CI 0.634-1.635),进展 HR 为 1.021(95%CI 0.694-1.501),3-5 级毒性无差异。曲阿平加入 CRT 未改善总生存。
要点
- 曲阿平加入顺铂放化疗未改善局部晚期宫颈癌和阴道癌患者的总生存。
- CRT 组与 CRT+T 组 3-5 级毒性发生率分别为 52% 与 49%,无差异。
- CRT+T 组报告 2 例 5 级毒性(心脏骤停和酸中毒)。
核心结论
- 曲阿平加入顺铂放化疗未改善总生存。
研究设计与样本
- NRG-GY006 是一项开放标签随机Ⅲ期试验,随机分配至 CRT 或 CRT 联合曲阿平(CRT+T)组。
- 共 450 例患者随机,448 例符合条件(CRT 组 224 例,CRT+T 组 224 例)。
- 纳入 FIGO 2009 局部晚期宫颈癌(IB2、II、IIIB 或 IVA 期)无腹主动脉旁淋巴结受累或 II-IV 期阴道癌患者。
- 放疗包括三维适形放疗(3DCRT)或图像引导调强放疗(IG-IMRT)后行腔内近距离放疗。
主要发现
- 中位年龄 47 岁(范围 23-85)。
- 93.3% 为宫颈癌,82% 为鳞状组织学;52% 为 FIGO II 期疾病。
- 随机时计划 IG-IMRT 者占 74.3%,计划 HDR 近距离放疗者占 98.2%。
- 3-5 级毒性:CRT 组 52% vs CRT+T 组 49%,无差异;CRT+T 组报告 2 例 5 级毒性(心脏骤停和酸中毒)。
- 中位随访 28 个月(IQR 15-45);死亡 HR 为 1.018(95%CI 0.634-1.635),进展 HR 为 1.021(95%CI 0.694-1.501)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cisplatin-based chemoradiation (CRT) plus brachytherapy for locally advanced cervical cancer (LACC) is standard. Intrinsic overexpression of ribonucleotide reductase (RNR) may enhance DNA damage repair from CRT. We report on outcomes of adding RNR inhibitor, triapine (T), to CRT. METHODS: NRG-GY006 is an open-label randomized phase III trial. FIGO 2009 LACC (stages IB2, II, IIIB or IVA) without para-aortic nodal involvement or stages II-IV vaginal cancer were eligible. Random assignment to CRT or in combination with thrice-weekly T (CRT + T) occurred. Radiation consisted of either 3D conformal (3DCRT) or image-guided intensity modulated RT (IG-IMRT) followed by intracavitary brachytherapy. Primary endpoint was overall survival (OS). Progression-free survival (PFS) was secondary. Exploratory endpoints included complete metabolic response rate on post treatment PET/CT imaging and comparative toxicity and outcomes for 3DCRT vs. IG-IMRT. FINDINGS: Four-hundred-fifty patients were randomized including 448 eligible (224 in CRT and 224 in CRT + T). Median age was 47 (range 23-85). The majority had cervical cancer (93.3 %) with squamous histology (82 %). 52 % had FIGO stage II disease. Racial/ethnic distribution included non-Hispanic white (53.8 %), black (15.2 %) and Hispanic/Latina (22.5 %). At randomization, IG-IMRT was planned in 74.3 % and HDR brachytherapy in 98.2 %. No differences in Grade 3-5 toxicities were observed: CRT: 52 % and CRT + T: 49 %, with two G5 toxicities (cardiac arrest and acidosis) in the CRT + T arm. The median patient follow-up was 28 months (IQR 15-45). HR for death was 1.018 (95 % CI 0.634-1.635) while HR for progression was 1.021 (95 % CI 0.694-1.501). INTERPRETATION: Triapine added to CRT did not improve OS.
引用
- Leath CA, Deng W, Mell LK, et al. Incorporation of triapine (T) to cisplatin chemoradiation (CRT) for locally advanced cervical and vaginal cancer: Results from NRG-GY006, a phase III randomized trial. Gynecol Oncol. 2025. PMID: 40101606. doi:10.1016/j.ygyno.2025.03.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。